BIONET is the first publicly listed company in Taiwan specializing in cell therapy. BIONET possesses the core technology and preparation capabilities of medical-grade cell therapy products. The company not only applies cell therapies to treat more than 60 types of diseases but also provides customized exosomes (Umbilical Cord Blood Exosomes, Amniotic Fluid Exosomes) services. In addition, The company’s own Mesenchymal Stem Cell bank was established in 2005. Under the “Regulations Governing the Application or Use of Specific Medical Techniques or Examinations, or Medical Devices“ passed by the Ministry of Health and Welfare in 2018, autologous adipose-derived stem cells are approved for indications such as osteoarthritis and chronic wounds, subcutaneous soft tissue defect and immune cells (CIK) for the treatment of various cancers such as colorectal cancer, lung cancer, breast cancer, and liver cancer.
Product Services: Umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, umbilical cord blood exosomes, amniotic fluid exosomes, adipose-derived mesenchymal stem cells, immune cells.
GGA is the first company in Taiwan that specializes in both "precision health/genomic medicine" and "digital medical technology," integrating capabilities in biomedicine and information technology. For many years, we have provided the medical community with various clinical testing and analysis reports. With our goal of delivering a "Patient-centered Total Testing Process," which involves comprehensive analysis and follow-up of all tests focused on achieving the best clinical outcomes for each patient, we actively pursue the implementation of all-encompassing precision health services across all age groups.
Product Services: Preconception Testing, Prenatal Testing, Newborn Testing, Adult Health & Cancer Risk Genetic Testing.